Premium
Re‐induction of complete remission with a new synthetic retinoid, Am‐80, for relapse of acute promyelocytic leukaemia previously treated with all‐ trans retinoic acid
Author(s) -
Takeuchi Makoto,
Yano Tomofumi,
Omoto Eijiro,
Takahashi Kiyoshi,
Kibata Masayoshi,
Shudo Koichi,
Ueda Ryuzo,
Ohno Ryuzo,
Harada Mine
Publication year - 1997
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1046/j.1365-2141.1997.182663.x
Subject(s) - retinoic acid , pancytopenia , acute promyelocytic leukemia , retinoid , bone marrow , chemotherapy , cancer research , chromosomal translocation , medicine , tretinoin , gene rearrangement , biology , gene , biochemistry
Two patients with relapsed acute promyelocytic leukaemia previously treated with all‐ trans retinoic acid (ATRA), were treated with a new synthetic retinoid, Am‐80. In both patients pancytopenia gradually resolved without an increase in leukaemic cells, and differentiation of leukaemic cells was observed morphologically in bone marrow. Without the use of anti‐leukaemic agents, both cases achieved complete remission (CR) on days 52 and 38 of treatment, respectively. On the day of CR, PML gene rearrangement and the t(15;17) translocation disappeared, though PML‐RAR α chimaeric messenger RNA was still detected by reverse transcriptase polymerase chain reaction. Both patients then received conventional chemotherapy for consolidation of CR. These clinical experiences suggest that Am‐80 may be an active agent for APL patients who have relapsed from ATRA‐induced remission.